Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study - PubMed
5 hours ago
- #Triple-negative breast cancer
- #Adjuvant therapy
- #Real-world evidence
- The study evaluates real-world treatment patterns and safety of adjuvant therapies following neoadjuvant chemoimmunotherapy for early-stage triple-negative breast cancer (TNBC).
- Among 726 patients, 692 underwent surgery, with 62.9% achieving pathologic complete response (pCR).
- For patients with pCR, 84.8% received adjuvant pembrolizumab alone, while 14.3% received no adjuvant therapy.
- Patients with residual disease and no germline BRCA1/2 mutations (n=207) mostly received pembrolizumab plus capecitabine (57.5%) or pembrolizumab alone (26.1%).
- BRCA1/2-mutated patients (n=26) predominantly received pembrolizumab plus olaparib (57.7%) or pembrolizumab alone (19.2%).
- Adjuvant pembrolizumab alone had a lower incidence of grade ≥3 adverse events (6.7%) compared to combination regimens.
- Drug discontinuation due to toxicity was 5.7% for pembrolizumab alone, 11.2% for pembrolizumab + capecitabine, and 7.7% for pembrolizumab + olaparib.
- Combination strategies were associated with higher rates of grade ≥3 adverse events, but their efficacy remains to be determined.